ProMIS Neurosciences annual stock-based compensation
2021
2022
2023
2024
2025
ProMIS Neurosciences Stock-Based Compensation Growth & History (PMN)
ProMIS Neurosciences's stock-based compensation was $857,628 for fiscal 2025.
View full ProMIS Neurosciences company overviewProMIS Neurosciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $857,628 | $31,820 | +3.85% |
| 2024 | 2024-12-31 | $825,808 | $554,266 | +204.12% |
| 2023 | 2023-12-31 | $271,542 | −$216,088 | −44.31% |
| 2022 | 2022-12-31 | $487,630 | −$27,999 | −5.43% |
| 2021 | 2021-12-31 | $515,629 | — | — |
ProMIS Neurosciences quarterly stock-based compensation
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $408,894 | $196,879 | +92.86% |
| Q1 2026 | 2026-03-31 | $189,425 | −$55,870 | −22.78% |
| Q4 2025 | 2025-12-31 | $203,171 | −$420,018 | −67.40% |
| Q3 2025 | 2025-09-30 | $197,147 | $76,111 | +62.88% |
| Q2 2025 | 2025-06-30 | $212,015 | $194,016 | +1077.93% |
| Q1 2025 | 2025-03-31 | $245,295 | $181,711 | +285.78% |
| Q4 2024 | 2024-12-31 | $623,189 | $618,348 | +12773.15% |
| Q3 2024 | 2024-09-30 | $121,036 | $121,036 | — |
| Q2 2024 | 2024-06-30 | $17,999 | −$116,192 | −86.59% |
| Q1 2024 | 2024-03-31 | $63,584 | −$68,926 | −52.02% |
| Q4 2023 | 2023-12-31 | $4,841 | −$133,928 | −96.51% |
| Q3 2023 | 2023-09-30 | $0 | −$108,584 | — |
| Q2 2023 | 2023-06-30 | $134,191 | $18,779 | +16.27% |
| Q1 2023 | 2023-03-31 | $132,510 | $7,645 | +6.12% |
| Q4 2022 | 2022-12-31 | $138,769 | — | — |
| Q3 2022 | 2022-09-30 | $108,584 | −$81,045 | −42.74% |
| Q2 2022 | 2022-06-30 | $115,412 | −$10,852 | −8.59% |
| Q1 2022 | 2022-03-31 | $124,865 | — | — |
| Q3 2021 | 2021-09-30 | $189,629 | — | — |
| Q2 2021 | 2021-06-30 | $126,264 | — | — |
ProMIS Neurosciences stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, ProMIS Neurosciences's stock-based compensation increased from $515,629 to $857,628, a change of $341,999. The latest reported quarter, Q2 2026, shows $408,894.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ProMIS Neurosciences source filings ↗